49B Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.00 |
| 52 Week High | US$17.30 |
| 52 Week Low | US$8.90 |
| Beta | 0.63 |
| 11 Month Change | -7.89% |
| 3 Month Change | 7.69% |
| 1 Year Change | 8.53% |
| 33 Year Change | -41.47% |
| 5 Year Change | -1.41% |
| Change since IPO | 26.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 49B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.4% | 0.8% | -1.3% |
| 1Y | 8.5% | -17.5% | 7.4% |
Return vs Industry: 49B exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 49B exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| 49B volatility | |
|---|---|
| 49B Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 49B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 49B's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,000 | John Oyler | www.beigene.com |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
BeiGene, Ltd. Fundamentals Summary
| 49B fundamental statistics | |
|---|---|
| Market cap | €19.69b |
| Earnings (TTM) | -€789.97m |
| Revenue (TTM) | €3.10b |
6.4x
P/S Ratio-25.0x
P/E RatioIs 49B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 49B income statement (TTM) | |
|---|---|
| Revenue | CN¥23.51b |
| Cost of Revenue | CN¥3.84b |
| Gross Profit | CN¥19.67b |
| Other Expenses | CN¥25.66b |
| Earnings | -CN¥5.99b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -56.41 |
| Gross Margin | 83.67% |
| Net Profit Margin | -25.50% |
| Debt/Equity Ratio | 29.6% |
How did 49B perform over the long term?
See historical performance and comparison